Cargando…
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
PURPOSE: Given the unmet need for novel immunotherapy in soft tissue sarcoma (STS), we sought to characterize the phenotype and function of intratumoral natural killer (NK) and T cells to identify novel strategies to augment tumor-infiltrating lymphocyte (TIL) function. EXPERIMENTAL DESIGN: Using pr...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651745/ https://www.ncbi.nlm.nih.gov/pubmed/33158916 http://dx.doi.org/10.1136/jitc-2020-001355 |
_version_ | 1783607590504103936 |
---|---|
author | Judge, Sean J Darrow, Morgan A Thorpe, Steve W Gingrich, Alicia A O'Donnell, Edmond F Bellini, Alyssa R Sturgill, Ian R Vick, Logan V Dunai, Cordelia Stoffel, Kevin M Lyu, Yue Chen, Shuai Cho, May Rebhun, Robert B Monjazeb, Arta M Murphy, William J Canter, Robert J |
author_facet | Judge, Sean J Darrow, Morgan A Thorpe, Steve W Gingrich, Alicia A O'Donnell, Edmond F Bellini, Alyssa R Sturgill, Ian R Vick, Logan V Dunai, Cordelia Stoffel, Kevin M Lyu, Yue Chen, Shuai Cho, May Rebhun, Robert B Monjazeb, Arta M Murphy, William J Canter, Robert J |
author_sort | Judge, Sean J |
collection | PubMed |
description | PURPOSE: Given the unmet need for novel immunotherapy in soft tissue sarcoma (STS), we sought to characterize the phenotype and function of intratumoral natural killer (NK) and T cells to identify novel strategies to augment tumor-infiltrating lymphocyte (TIL) function. EXPERIMENTAL DESIGN: Using prospectively collected specimens from dogs and humans with sarcomas, archived specimens, and The Cancer Genome Atlas (TCGA) data, we evaluated blood and tumor NK and T cell phenotype and function and correlated those with outcome. We then assessed the effects of interleukin 15 (IL-15) stimulation on both NK and T cell activation and TIGIT upregulation. Finally, we evaluated cytotoxic effects of IL-15 combined with TIGIT blockade using a novel anti-TIGIT antibody. RESULTS: TILs were strongly associated with survival outcome in both archived tissue and TCGA, but higher TIL content was also associated with higher TIGIT expression. Compared with blood, intratumoral NK and T cells showed significantly higher expression of both activation and exhaustion markers, in particular TIGIT. Ex vivo stimulation of blood and tumor NK and T cells from patients with STS with IL-15 further increased both activation and exhaustion markers, including TIGIT. Dogs with metastatic osteosarcoma receiving inhaled IL-15 also exhibited upregulation of activation markers and TIGIT. Ex vivo, combined IL-15 and TIGIT blockade using STS blood and tumor specimens significantly increased cytotoxicity against STS targets. CONCLUSION: Intratumoral NK and T cells are prognostic in STS, but their activation is marked by significant upregulation of TIGIT. Our data suggest that combined IL-15 and TIGIT blockade may be a promising clinical strategy in STS. |
format | Online Article Text |
id | pubmed-7651745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-76517452020-11-17 Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas Judge, Sean J Darrow, Morgan A Thorpe, Steve W Gingrich, Alicia A O'Donnell, Edmond F Bellini, Alyssa R Sturgill, Ian R Vick, Logan V Dunai, Cordelia Stoffel, Kevin M Lyu, Yue Chen, Shuai Cho, May Rebhun, Robert B Monjazeb, Arta M Murphy, William J Canter, Robert J J Immunother Cancer Clinical/Translational Cancer Immunotherapy PURPOSE: Given the unmet need for novel immunotherapy in soft tissue sarcoma (STS), we sought to characterize the phenotype and function of intratumoral natural killer (NK) and T cells to identify novel strategies to augment tumor-infiltrating lymphocyte (TIL) function. EXPERIMENTAL DESIGN: Using prospectively collected specimens from dogs and humans with sarcomas, archived specimens, and The Cancer Genome Atlas (TCGA) data, we evaluated blood and tumor NK and T cell phenotype and function and correlated those with outcome. We then assessed the effects of interleukin 15 (IL-15) stimulation on both NK and T cell activation and TIGIT upregulation. Finally, we evaluated cytotoxic effects of IL-15 combined with TIGIT blockade using a novel anti-TIGIT antibody. RESULTS: TILs were strongly associated with survival outcome in both archived tissue and TCGA, but higher TIL content was also associated with higher TIGIT expression. Compared with blood, intratumoral NK and T cells showed significantly higher expression of both activation and exhaustion markers, in particular TIGIT. Ex vivo stimulation of blood and tumor NK and T cells from patients with STS with IL-15 further increased both activation and exhaustion markers, including TIGIT. Dogs with metastatic osteosarcoma receiving inhaled IL-15 also exhibited upregulation of activation markers and TIGIT. Ex vivo, combined IL-15 and TIGIT blockade using STS blood and tumor specimens significantly increased cytotoxicity against STS targets. CONCLUSION: Intratumoral NK and T cells are prognostic in STS, but their activation is marked by significant upregulation of TIGIT. Our data suggest that combined IL-15 and TIGIT blockade may be a promising clinical strategy in STS. BMJ Publishing Group 2020-11-06 /pmc/articles/PMC7651745/ /pubmed/33158916 http://dx.doi.org/10.1136/jitc-2020-001355 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Clinical/Translational Cancer Immunotherapy Judge, Sean J Darrow, Morgan A Thorpe, Steve W Gingrich, Alicia A O'Donnell, Edmond F Bellini, Alyssa R Sturgill, Ian R Vick, Logan V Dunai, Cordelia Stoffel, Kevin M Lyu, Yue Chen, Shuai Cho, May Rebhun, Robert B Monjazeb, Arta M Murphy, William J Canter, Robert J Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas |
title | Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas |
title_full | Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas |
title_fullStr | Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas |
title_full_unstemmed | Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas |
title_short | Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas |
title_sort | analysis of tumor-infiltrating nk and t cells highlights il-15 stimulation and tigit blockade as a combination immunotherapy strategy for soft tissue sarcomas |
topic | Clinical/Translational Cancer Immunotherapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651745/ https://www.ncbi.nlm.nih.gov/pubmed/33158916 http://dx.doi.org/10.1136/jitc-2020-001355 |
work_keys_str_mv | AT judgeseanj analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT darrowmorgana analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT thorpestevew analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT gingrichaliciaa analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT odonnelledmondf analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT bellinialyssar analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT sturgillianr analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT vickloganv analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT dunaicordelia analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT stoffelkevinm analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT lyuyue analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT chenshuai analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT chomay analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT rebhunrobertb analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT monjazebartam analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT murphywilliamj analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas AT canterrobertj analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas |